Next Article in Journal
BPA and BPS Affect Connexin 37 in Bovine Cumulus Cells
Next Article in Special Issue
BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer
Previous Article in Journal
Meta-Analysis of Gene Popularity: Less Than Half of Gene Citations Stem from Gene Regulatory Networks
Previous Article in Special Issue
Expression of BARD1 β Isoform in Selected Pediatric Tumors
Brief Report

Differential Expression of BARD1 Isoforms in Melanoma

1
Department of Pathology, Otago Medical School, Dunedin Campus, University of Otago, Dunedin 9010, New Zealand
2
Department of Biology and Medical Genetics, Medical University of Gdansk, 80-211 Gdansk, Poland
3
Department of Pathology and Biomedical Science, University of Otago, Christchurch 8011, New Zealand
4
Department of Tumour Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, 8011 Cracow, Poland
5
Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, 8011 Cracow, Poland
6
Maurice Wilkins Centre for Molecular Biodiscovery, Auckland 1010, New Zealand
*
Author to whom correspondence should be addressed.
Authors contributed equally to this work.
Academic Editors: Rajiv Kumar and Robert Winqvist
Genes 2021, 12(2), 320; https://doi.org/10.3390/genes12020320
Received: 24 December 2020 / Revised: 12 February 2021 / Accepted: 20 February 2021 / Published: 23 February 2021
(This article belongs to the Special Issue BARD1 in Cancer)
Melanoma comprises <5% of cutaneous malignancies, yet it causes a significant proportion of skin cancer-related deaths worldwide. While new therapies for melanoma have been developed, not all patients respond well. Thus, further research is required to better predict patient outcomes. Using long-range nanopore sequencing, RT-qPCR, and RNA sequencing analyses, we examined the transcription of BARD1 splice isoforms in melanoma cell lines and patient tissue samples. Seventy-six BARD1 mRNA variants were identified in total, with several previously characterised isoforms (γ, φ, δ, ε, and η) contributing to a large proportion of the expressed transcripts. In addition, we identified four novel splice events, namely, Δ(E3_E9), ▼(i8), IVS10+131▼46, and IVS10▼176, occurring in various combinations in multiple transcripts. We found that short-read RNA-Seq analyses were limited in their ability to predict isoforms containing multiple non-contiguous splicing events, as compared to long-range nanopore sequencing. These studies suggest that further investigations into the functional significance of the identified BARD1 splice variants in melanoma are warranted. View Full-Text
Keywords: melanoma; BARD1; nanopore sequencing; RNA-Seq melanoma; BARD1; nanopore sequencing; RNA-Seq
Show Figures

Figure 1

MDPI and ACS Style

McDougall, L.I.; Powell, R.M.; Ratajska, M.; Lynch-Sutherland, C.F.; Hossain, S.M.; Wiggins, G.A.R.; Harazin-Lechowska, A.; Cybulska-Stopa, B.; Motwani, J.; Macaulay, E.C.; Reid, G.; Walker, L.C.; Ryś, J.; Eccles, M.R. Differential Expression of BARD1 Isoforms in Melanoma. Genes 2021, 12, 320. https://doi.org/10.3390/genes12020320

AMA Style

McDougall LI, Powell RM, Ratajska M, Lynch-Sutherland CF, Hossain SM, Wiggins GAR, Harazin-Lechowska A, Cybulska-Stopa B, Motwani J, Macaulay EC, Reid G, Walker LC, Ryś J, Eccles MR. Differential Expression of BARD1 Isoforms in Melanoma. Genes. 2021; 12(2):320. https://doi.org/10.3390/genes12020320

Chicago/Turabian Style

McDougall, Lorissa I., Ryan M. Powell, Magdalena Ratajska, Chi F. Lynch-Sutherland, Sultana M. Hossain, George A.R. Wiggins, Agnieszka Harazin-Lechowska, Bożena Cybulska-Stopa, Jyoti Motwani, Erin C. Macaulay, Glen Reid, Logan C. Walker, Janusz Ryś, and Michael R. Eccles. 2021. "Differential Expression of BARD1 Isoforms in Melanoma" Genes 12, no. 2: 320. https://doi.org/10.3390/genes12020320

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop